Publications

Skip to content

Publications

Explore Flatiron-authored research

Analysis of real-world progression and insufficient response variables and related endpoints among patients with non-Hodgkin lymphoma

Advances in Therapy

Richey M, Fullerton C, Zhang Q, et al

March 2025

publication-summary-analysis-of-real-world-progression-with-insufficient-response-variables-and-related-endpoints-among-patients-with-non-hodgkin-lymphoma

2,000 publications—and counting

To date, over 2,000 publications—authored by either Flatiron or our partners—have used Flatiron’s real-world data

Explore a list of all publications

See the impact of our data

Database Characterization Guide

An overview of Flatiron Health EHR-derived US data for journal reviewers and readers to better understand the data used in publications

Review our guide

Explore our summaries of Flatiron-authored research

Disease area

Acute myeloid leukemia

Breast cancer

Chronic lymphocytic leukemia

Colorectal cancer

Diffuse large B-Cell lymphoma

Gastric/Esophageal cancer

Head and neck cancer

Hepatocellular carcinoma

Melanoma

Metastatic breast cancer

Multiple myeloma

Non-small cell lung cancer

Ovarian cancer

Pancreatic cancer

Prostate cancer

Renal cell carcinoma

Small cell lung cancer

Tumor agnostic

Urothelial cell carcinoma

Topics

Comparative effectiveness

Drug discovery

HTA and market access

Health equity

Label expansion

Machine learning

Methodology

Prospective study

Quality improvement

Quality reporting

Regulatory

Resistance ID

Treatment patterns

Unmet need

Showing 9 of 0 results

ASCO Annual Meeting
May 2026
From plenary to practice: A large language model (LLM)-based thematic analysis of landmark clinical trial discussions and factors influencing their real-world adoption
Cohen AB, Williams T, Aggarwal C, et al.
ASCO Annual Meeting
May 2026
Real-world biomarker testing rates, targeted therapy use, and clinical outcomes in patients with advanced gastric or GEJ cancer in the United States
Damato L, Liao NS, Bryan J, Hankinson EA, Castellanos E.
ASCO Annual Meeting
May 2026
Using ML to predict rapid progression for patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4/6 inhibitors (CDK 4/6i)
Peng M, Rios G, Estevez M, et al.
ASCO Annual Meeting
May 2026
Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first- line induction and maintenance regimens in extensive-stage small cell lung cancer
Ganti AK, Snider J, Yan J, et al.
ASCO Annual Meeting
May 2026
Digital twin models for counterfactual prediction in NSCLC: a validation study using clinical trial data
Cohen AB, Giffith S, Estevez M, et al.
ASCO Annual Meeting
May 2026
Platinum re-challenge in platinum-resistant ovarian cancer: real-world patterns and outcomes
Yerram P, Bye M, Patel K, Nasrallah N, Curry M, Castellanos E.
ASCO Annual Meeting
May 2026
Drivers of organotropism and patterns of metastatic progression in metastatic non-small cell lung cancer
ASCO Annual Meeting
May 2026
Machine learning risk stratification in a US-based database to identify subgroups of patients with PD-L1-high NSCLC who benefit from adding chemotherapy to pembrolizumab
Orcutt X, Nimgaonkar V, Sun L, et al.
ASCO Annual Meeting
May 2026
Real-world treatment patterns and outcomes among patients with high-risk and very high-risk non-metastatic prostate cancer
Hankinson EA, Qian Y, Ward P, Patel K, Dolor A, Sujenthiran A.

Real answers to guide oncology’s highest-stakes decisions.

Resources
Publications
Company
Media
Careers
Contact Us

Real-World Evidence
Point of Care

Legal, Privacy, and Compliance
Cookie Settings
© FLATIRON HEALTH® 2026